Embryotoxicity and teratogenic effect of chemotherapeutic antiviral drug

The purpose of this study was to investigate theembryotoxic and teratogenic effects of an antiviral drug, Triazavirin. The main objective of the study was to explore this issue on a biological model - white mice, to get two generations (F1, F2) and analyze their number, offspring, its size and weight. We formed two groups of 20 mice - experimental and control (F0). From the first days of pregnancy to the delivery day the mice were treated with Triazavirin drug at a dose of 0.002 g diluted with 0.2 mL of saline solution. The drug solution was administrated intragastrically with a probe, once a day. Killing of 10 mice was carried out on the 20th day, before delivery; on the 21st day other mice delivered the first generation of offspring (F1). By the age of 3 months the survival rate of mice offspring (F1) was 85.93% in the experimental group and 84.61% in the control group.15 male mice and 30 female mice were selected out of the obtained litter (F1) in the experimental group. No drug administration to the selected mice. The control group was formed. The mice mated and delivered a new litter (F2). On the 21st day the pregnant mice delivered the second generation of offspring (F2). In the experimental group an average litter per one female mouse was 7.1, in the control group this number was 7. By the age of 3 months the survival rate in the experimental group was 76.06%, and in the control group acceptable. During the autopsy of all generations of pregnant female mice and fetuses examination no severe development defects or hemorrhages were found, all fetuses were alive. Administration of the drug throughout the pregnancy period (during the preimplant, implant, and organogenesis periods) causes no embryotoxic or teratogenic effects. No increase in fetal mortality rate as compared to the control rate or significant deviations in the size and weight of new-born, 1-month-old and 3-month-old mice were noticed. During the autopsy of female mice no high rate of pre- and post-implant mortality was noticed. No visible changes were found during the autopsy and examination of the female and fetuses in the experimental group.

мыши, плоды, эмбриотоксичность, тератогенный эффект, противовирусный препарат, mice, fetuses, embryotoxicity, teratogenic effect, antiviral drug

1. ГОСТ 32379-2013. Методы испытания по воздействию химической продукции на организм человека. Испытания по оценке репродуктивной эмбриональной токсичности (скрининговый метод). / М.: Стандартинформ, - 2014. - 10 с.

2. Гуськова, Т.А. Токсикология лекарственных веществ / Т.А. Гуськова // Москва, - 2008. - С. 27-30.

3. Руководство по проведению доклинических исследований лекарственных средств. Часть 1. - М.: Гриф и К, 2012. -944 с.

4. Смольникова, Н.М. Методические указания по изучению репродуктивной токсичности фармакологических веществ / Н.М. Смольникова, Б.И. Любимов, А.Д. Дурнев // Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. - М., - 2005. - С. 87-100.

5. Хабриев, Р.У. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / Р.У. Харбиев // М.: Медицина. 2005. 839 с.

6. Eric, M. Teratogenicity of antibacterial agents / М. Eric, А. Sabo // Collegium antropologicum. - v. 32. - № 3. - 2008. - р. 919 -925.

7. The European Agency for the Evaluation of Medicinal Products. Committee for veterinary medicinal products. Florfenicol. Summary report (1).

8. The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit. EMEA/MRL/497/98-FINAL. Committee for veterinary medicinal products. Lincomycin. Summary report (1).